BMS-707035HIV-I integrase inhibitor,potent and specific CAS# 729607-74-3 |
- Nelfinavir Mesylate
Catalog No.:BCC1794
CAS No.:159989-65-8
- Fluorouracil (Adrucil)
Catalog No.:BCC2135
CAS No.:51-21-8
- HIV-1 integrase inhibitor
Catalog No.:BCC1618
CAS No.:544467-07-4
- Elvitegravir (GS-9137)
Catalog No.:BCC2134
CAS No.:697761-98-1
- MK-2048
Catalog No.:BCC2136
CAS No.:869901-69-9
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
| Cas No. | 729607-74-3 | SDF | Download SDF |
| PubChem ID | 54682040 | Appearance | Powder |
| Formula | C17H19FN4O5S | M.Wt | 410.4 |
| Type of Compound | N/A | Storage | Desiccate at -20°C |
| Solubility | DMSO : 50 mg/mL (121.83 mM; Need ultrasonic) H2O : < 0.1 mg/mL (insoluble) | ||
| Chemical Name | 2-(1,1-dioxothiazinan-2-yl)-N-[(4-fluorophenyl)methyl]-5-hydroxy-1-methyl-6-oxopyrimidine-4-carboxamide | ||
| SMILES | CN1C(=O)C(=C(N=C1N2CCCCS2(=O)=O)C(=O)NCC3=CC=C(C=C3)F)O | ||
| Standard InChIKey | VNIWZCGZPBJWBI-UHFFFAOYSA-N | ||
| Standard InChI | InChI=1S/C17H19FN4O5S/c1-21-16(25)14(23)13(15(24)19-10-11-4-6-12(18)7-5-11)20-17(21)22-8-2-3-9-28(22,26)27/h4-7,23H,2-3,8-10H2,1H3,(H,19,24) | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
| Description | BMS-707035 is a specific inhibitor of HIV-I integrase with IC50 value of 15 nM. | |||||
| Targets | HIV-I integrase | |||||
| IC50 | 15 nM | |||||
BMS-707035 Dilution Calculator
BMS-707035 Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 2.4366 mL | 12.1832 mL | 24.3665 mL | 48.7329 mL | 60.9162 mL |
| 5 mM | 0.4873 mL | 2.4366 mL | 4.8733 mL | 9.7466 mL | 12.1832 mL |
| 10 mM | 0.2437 mL | 1.2183 mL | 2.4366 mL | 4.8733 mL | 6.0916 mL |
| 50 mM | 0.0487 mL | 0.2437 mL | 0.4873 mL | 0.9747 mL | 1.2183 mL |
| 100 mM | 0.0244 mL | 0.1218 mL | 0.2437 mL | 0.4873 mL | 0.6092 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
BMS-707035 is a specific HIV-I integrase (IN) inhibitor with IC50 value of 15 nM [1].
Retroviral IN is an enzyme produced by a retrovirus (such as HIV) that enables its genetic material to be integrated into the DNA of the infected cell. IN is a key component in the retroviral pre-integration complex (PIC) [1].
BMS-707035 is an investigational IN inhibitor. However, the IN mutations V75I, Q148R, V151I, and G163R are found to have resistance to BMS-707035. The inhibition of strand transfer activity by BMS-707035 is overcome when increasing amount of target DNA, so the binding of BMS-707035 to IN and target DNA to IN are mutually exclusive. The four terminal bases at the 5' end of LTR can affect the binding of BMS-707035 to IN [3]. The 3' terminus of the viral LTR can regulate the kinetics of binding and dissociation, which will then retard the rate of BMS-707035 association with IN [2].
References:
[1]. Cotelle P. 3-Hydroxy-6,7-dihydropyrimido[2,1-c][1,4]oxazin-4(9H)-ones as new HIV-1 integrase inhibitors WO2011046873 A1. Expert Opin. Ther Patents, 2011, 21(11): 1799-1804.
[2]. Langley DR, Samanta HK, Lin Z, et al. The terminal (catalytic) adenosine of the HIV LTR controls the kinetics of binding and dissociation of HIV integrase strand transfer inhibitors. Biochemistry, 2008, 47(51): 13481-13488.
- XRP44X
Catalog No.:BCC7568
CAS No.:729605-21-4
- Gomisin O
Catalog No.:BCN2875
CAS No.:72960-22-6
- Gomisin E
Catalog No.:BCN7031
CAS No.:72960-21-5
- 6,7-Dihydroneridienone A
Catalog No.:BCN4020
CAS No.:72959-46-7
- 2-Furoyl-LIGRLO-amide
Catalog No.:BCC3958
CAS No.:729589-58-6
- Carvedilol
Catalog No.:BCC4324
CAS No.:72956-09-3
- DL-Catechin
Catalog No.:BCN6325
CAS No.:7295-85-4
- 30-Hydroxylup-20(29)-en-3-one
Catalog No.:BCN4286
CAS No.:72944-06-0
- Octadecyl p-coumarate
Catalog No.:BCN7235
CAS No.:72943-88-5
- K858
Catalog No.:BCC7760
CAS No.:72926-24-0
- Bohemamine
Catalog No.:BCN1958
CAS No.:72926-12-6
- (RS)-4-Carboxyphenylglycine
Catalog No.:BCC6601
CAS No.:7292-81-1
- Brassinolide
Catalog No.:BCC1438
CAS No.:72962-43-7
- L-(-)-threo-3-Hydroxyaspartic acid
Catalog No.:BCC6565
CAS No.:7298-99-9
- Cordycepin
Catalog No.:BCN5389
CAS No.:73-03-0
- H-Trp-OH
Catalog No.:BCC3111
CAS No.:73-22-3
- Adenine
Catalog No.:BCC4450
CAS No.:73-24-5
- Melatonin
Catalog No.:BCN2196
CAS No.:73-31-4
- H-Ile-OH
Catalog No.:BCC2960
CAS No.:73-32-5
- Guanine
Catalog No.:BCN8414
CAS No.:73-40-5
- Lidocaine hydrochloride
Catalog No.:BCC9009
CAS No.:73-78-9
- 15-Isopimarene-8,18-diol
Catalog No.:BCN4287
CAS No.:73002-86-5
- CyPPA
Catalog No.:BCC7526
CAS No.:73029-73-9
- Atractylenolide III
Catalog No.:BCN1045
CAS No.:73030-71-4
3-Hydroxy-6,7-dihydropyrimido[2,1-c][1,4]oxazin-4(9H)-ones as new HIV-1 integrase inhibitors WO2011046873 A1.[Pubmed:21974685]
Expert Opin Ther Pat. 2011 Nov;21(11):1799-804.
Since the discovery of raltegravir, the first FDA-approved integrase inhibitor, Merck and other pharmaceutical companies have continued their research programs in order to introduce novel molecules as second generation integrase inhibitors. Elvitegravir (Japan Tobacco/Gilead) and dolutegravir (Shionogi/GlaxoSmithKline) are in advanced stages of clinical development. Bristol-Myers Squibb has developed molecules leading to BMS-707035, which was stopped at the Phase II clinical trial stage. Herein is presented the last patent from this company where, in particular, new 3-hydroxy-6,7-dihydropyrimido[2,1-c][1,4]oxazin-4(9H)-ones are synthesized and their biological properties given.
HIV-1 integrase inhibitors: an emerging clinical reality.[Pubmed:17472411]
Drugs R D. 2007;8(3):155-68.
From the discovery of HIV-1 integrase (IN) inhibitors using enzyme-based assays in 1992, it has taken 15 years to achieve success in human clinical trials. Currently available antiretroviral drugs set high clinical standards in efficacy and long-term safety for upcoming novel HIV/AIDS therapeutic agents. The results from advanced stages of human clinical trials with IN inhibitors indicate a promising future for these compounds as a novel class of antiretroviral drugs. Success and failure of previously discovered antiretroviral drugs have taught us that there are no magic bullets in eradicating HIV. However, approval of drugs selectively targeting IN has long been awaited. There is once again a surge of interest in the field focusing on clinical development of IN inhibitors. Here, we summarise the current status of IN inhibitors under clinical development. These agents include S-1360, GSK-364735, L-870,810, L-870,812, MK-0518, GS-9137, L-900564, GS-9224, and BMS-707035. Promising antiviral activity has already been achieved with MK-0518 and GS-9137 in late-stage clinical studies.
Anti-infectives: clinical progress of HIV-1 integrase inhibitors.[Pubmed:18537517]
Expert Opin Emerg Drugs. 2008 Jun;13(2):213-25.
BACKGROUND: HIV-1 integrase (IN) represents a therapeutically advantageous viral target to treat HIV/AIDS in the clinic. Over a decade of progress in the field has resulted in IN inhibitor chemical classes that display specificity for strand transfer catalysis of the enzyme, thus blocking viral DNA integration into host cell nuclear DNA, an essential step for viral infectivity. OBJECTIVE: In this manuscript we provide an update on recent HIV-1 IN inhibitors that have been clinically evaluated, which include MK-0518, MK-2048, GS-9137, GS-9160, GS-9224, GSK-364735, and BMS-707035. The information presented here can aid in the IN drug developmental process. METHODS: We have limited the scope of this review to information available on the clinical evaluation of promising strand transfer-specific IN inhibitors and their potential drug-drug interaction profiles with other antiretroviral agents. RESULTS/CONCLUSION: The development of strand transfer-specific inhibitor classes is an important achievement for the IN drug design and development field. However, continued drug development is needed given that the ability of HIV to replicate under therapeutic pressure will undoubtedly lead to the emergence of IN drug-resistant viral strains.
